NCT06054529

Spatiotemporal Dimensions of Metabolism in Autochthonous Tumors of GBM Patients

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 2 (estimated)
• Sponsor: AdventHealth Translational Research Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: —

Summary

To learn how altered metabolism in GBM causes tumor growth and resistance to drug therapy. In this pilot research study, we will dose GBM patients with a form of nicotinamide (a natural vitamin) that we can track. The nicotinamide will be converted to methyl nicotinamide (MeNAM) in the tumor. We will measure how fast the nicotinamide is converted to methyl nicotinamide. We believe that the speed of this chemical reaction in the tumor (fast versus slow) may be correlated with GBM aggressiveness

Conditions

• Glioblastoma Multiforme

Interventions

Type	Name	Description
PROCEDURE	Surgical removal of the GBM tumor	Surgical removal of the GBM tumor
OTHER	d4-NAM infusion	Following the surgical removal of the GBM tumor, GBM patients will be dosed with a form of nicotinamide (a natural vitamin) that we can track. The nicotinamide will be converted to methyl nicotinamide (MeNAM) in the tumor. We will measure how fast the nicotinamide is converted to methyl nicotinamide. We believe that the speed of this chemical reaction in the tumor (fast versus slow) may be correlated with GBM aggressiveness.

Timeline

• Start date: 2023-09-11
• Primary completion: 2024-01-22
• Completion: 2025-12-01
• First posted: 2023-09-26
• Last updated: 2025-03-13

Locations

1 site across 1 country: United States